138 related articles for article (PubMed ID: 11689657)
21. Allele-specific adaptation of poliovirus VP1 B-C loop variants to mutant cell receptors.
Liao S; Racaniello V
J Virol; 1997 Dec; 71(12):9770-7. PubMed ID: 9371643
[TBL] [Abstract][Full Text] [Related]
22. Peptide profiling of the route from Mahoney to Sabin, and return.
Kanduc D; Fasano C; Bavaro SL; Novello G; Lucchese G; Capone G
J Basic Microbiol; 2014 May; 54(5):369-77. PubMed ID: 23686793
[TBL] [Abstract][Full Text] [Related]
23. Growth phenotypes and biosafety profiles in poliovirus-receptor transgenic mice of recombinant oncolytic polio/human rhinoviruses.
Cello J; Toyoda H; Dejesus N; Dobrikova EY; Gromeier M; Wimmer E
J Med Virol; 2008 Feb; 80(2):352-9. PubMed ID: 18098139
[TBL] [Abstract][Full Text] [Related]
24. Host range determinants located on the interior of the poliovirus capsid.
Moss EG; Racaniello VR
EMBO J; 1991 May; 10(5):1067-74. PubMed ID: 1850692
[TBL] [Abstract][Full Text] [Related]
25. [Molecular genetic analysis of poliovirus infection].
Nomoto A
Yakugaku Zasshi; 1989 Sep; 109(9):622-35. PubMed ID: 2481725
[TBL] [Abstract][Full Text] [Related]
26. Engineering a poliovirus type 2 antigenic site on a type 1 capsid results in a chimaeric virus which is neurovirulent for mice.
Martin A; Wychowski C; Couderc T; Crainic R; Hogle J; Girard M
EMBO J; 1988 Sep; 7(9):2839-47. PubMed ID: 2460345
[TBL] [Abstract][Full Text] [Related]
27. Mapping of mutations contributing to the temperature sensitivity of the Sabin 1 vaccine strain of poliovirus.
Georgescu MM; Tardy-Panit M; Guillot S; Crainic R; Delpeyroux F
J Virol; 1995 Sep; 69(9):5278-86. PubMed ID: 7636970
[TBL] [Abstract][Full Text] [Related]
28. Analysis of neutralization-escape mutants selected from a mouse virulent type 1/type 2 chimeric poliovirus: identification of a type 1 poliovirus with antigenic site 1 deleted.
Couderc T; Martin A; Wychowski C; Girard M; Horaud F; Crainic R
J Gen Virol; 1991 Apr; 72 ( Pt 4)():973-7. PubMed ID: 1707949
[TBL] [Abstract][Full Text] [Related]
29. A mutation in the RNA polymerase of poliovirus type 1 contributes to attenuation in mice.
Tardy-Panit M; Blondel B; Martin A; Tekaia F; Horaud F; Delpeyroux F
J Virol; 1993 Aug; 67(8):4630-8. PubMed ID: 8392604
[TBL] [Abstract][Full Text] [Related]
30. Development of candidates for new type 2 and type 3 oral poliovirus vaccines.
Kohara M; Abe S; Yoshioka I; Nomoto A
Dev Biol Stand; 1993; 78():141-8. PubMed ID: 8388824
[TBL] [Abstract][Full Text] [Related]
31. [Reevaluate the effect of G-480 point mutation that determines the neurovirulence of type I vaccine polioviruses].
Zhang Y; Yan DM; Wang DY; Zhao R; Zhang DY; Ye XF; Zhu SL; An HQ; Xu WB
Bing Du Xue Bao; 2007 Jan; 23(1):1-8. PubMed ID: 17886713
[TBL] [Abstract][Full Text] [Related]
32. Correlation between poliovirus type 1 Mahoney replication in blood cells and neurovirulence.
Freistadt MS; Eberle KE
J Virol; 1996 Sep; 70(9):6486-92. PubMed ID: 8709287
[TBL] [Abstract][Full Text] [Related]
33. Neurovirulence of the intertypic poliovirus recombinant v3/a1-25: characterization of strains isolated from the spinal cord of diseased monkeys and evaluation of the contribution of the 3' half of the genome.
Agol VI; Drozdov SG; Frolova MP; Grachev VP; Kolesnikova MS; Kozlov VG; Ralph NM; Romanova LI; Tolskaya EA; Viktorova EG
J Gen Virol; 1985 Feb; 66 ( Pt 2)():309-16. PubMed ID: 2981970
[TBL] [Abstract][Full Text] [Related]
34. Mouse adaptation determinants of poliovirus type 1 enhance viral uncoating.
Couderc T; Delpeyroux F; Le Blay H; Blondel B
J Virol; 1996 Jan; 70(1):305-12. PubMed ID: 8523541
[TBL] [Abstract][Full Text] [Related]
35. Neurovirulence of Sabin 1-derived polioviruses isolated from an immunodeficient patient with prolonged viral excretion.
Yoneyama T; Yoshida H; Shimizu H; Yoshii K; Nagata N; Kew O; Miyamura T
Dev Biol (Basel); 2001; 105():93-8. PubMed ID: 11763343
[TBL] [Abstract][Full Text] [Related]
36. Determinants in the 5' noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype.
Kawamura N; Kohara M; Abe S; Komatsu T; Tago K; Arita M; Nomoto A
J Virol; 1989 Mar; 63(3):1302-9. PubMed ID: 2536835
[TBL] [Abstract][Full Text] [Related]
37. Selective cleavage by trypsin of the capsid protein VP1 of type 3 poliovirus results in improved sorting of cell bound virions.
Piirainen L; Airaksinen A; Hovi T; Roivainen M
Arch Virol; 1996; 141(6):1011-20. PubMed ID: 8712919
[TBL] [Abstract][Full Text] [Related]
38. The human poliovirus receptor. Receptor-virus interaction and parameters of disease specificity.
Gromeier M; Lu HH; Bernhardt G; Harber JJ; Bibb JA; Wimmer E
Ann N Y Acad Sci; 1995 May; 753():19-36. PubMed ID: 7611627
[TBL] [Abstract][Full Text] [Related]
39. Construction and properties of intertypic poliovirus recombinants: first approximation mapping of the major determinants of neurovirulence.
Agol VI; Grachev VP; Drozdov SG; Kolesnikova MS; Kozlov VG; Ralph NM; Romanova LI; Tolskaya EA; Tyufanov AV; Viktorova EG
Virology; 1984 Jul; 136(1):41-55. PubMed ID: 6330995
[TBL] [Abstract][Full Text] [Related]
40. A mouse model for poliovirus neurovirulence identifies mutations that attenuate the virus for humans.
La Monica N; Almond JW; Racaniello VR
J Virol; 1987 Sep; 61(9):2917-20. PubMed ID: 3039178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
